Silence Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLN research report →
About the company
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
- CEO
- Iain Gladstone Ross
- IPO
- 2020
- Employees
- 116
- HQ
- London, GB
Price Chart
- Market Cap
- $490.76M
- P/E
- -2.41
- P/S
- 532.57
- P/B
- 9.93
- EV/EBITDA
- -6.21
- Div Yield
- 0.00%
- Gross Margin
- 66.43%
- Op Margin
- -9396.64%
- Net Margin
- -9243.05%
- ROE
- -121.71%
- ROIC
- -82.66%
- Revenue
- $559.00K · -98.71%
- Net Income
- $-88,612,000 · -95.57%
- EPS
- $-1.89 · 20.25%
- Op Income
- $-89,753,000
- FCF YoY
- -14.95%
- 52W High
- $11.06
- 52W Low
- $4.19
- 50D MA
- $7.33
- 200D MA
- $6.30
- Beta
- 1.48
- Avg Volume
- 396.39K
Get TickerSpark's AI analysis on SLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 25 | Griffiths Richard Ian | buy | 20,000 |
| Oct 27, 25 | Griffiths Richard Ian | buy | 2,000 |
| Oct 27, 25 | Griffiths Richard Ian | sell | 2,000 |
| Aug 3, 25 | Griffiths Richard Ian | sell | 20,000 |
| Jan 2, 26 | Ede-Golightly James | other | 90,000 |
| Jan 2, 26 | MCINERNEY TIMOTHY | other | 90,000 |
| Jan 2, 26 | Romano Steven J. | other | 300,000 |
| Jan 2, 26 | HELLUMS RHONDA LYNETTE | other | 375,000 |
| Jan 2, 26 | Lemus David | other | 90,000 |
| Dec 18, 25 | Ross Iain | other | 900,000 |
Our SLN coverage
Recent articles, reports, and earnings notes.
No research on SLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLN report →Similar companies
Peers in the same neighborhood.